Last Updated on November 29, 2024 by The Health Master
Standing Committee
The Department Related Standing Committee on Chemicals and Fertilizers, chaired by Lok Sabha member Kirti Azad Jha, is gearing up to scrutinize critical areas within the pharmaceutical sector.
Key concerns, including the surge in medicine prices and the need for robust regulatory oversight, are at the forefront of the Committee’s agenda.
Key Areas of Investigation
The Standing Committee has identified six primary areas for investigation:
- Price Hike Scrutiny: A deep dive into the factors contributing to the rising cost of medicines and its impact on public health.
- Regulatory Reform: A comprehensive evaluation of the current regulatory framework and the urgency for stringent reforms to ensure drug quality and safety.
- Spurious Drug Control: A review of regulatory measures to combat the proliferation of counterfeit and substandard drugs.
- API Self-Sufficiency: An assessment of government initiatives, such as the Production Linked Incentive (PLI) scheme, aimed at boosting domestic API production.
- NIPER Performance: An evaluation of the performance and contributions of National Institutes of Pharmaceutical Education and Research (NIPERs) to the pharmaceutical sector.
- Indigenous Medicine Promotion: A review of strategies to promote traditional and indigenous medicine practices while adhering to stringent quality and safety standards.
The Role of the Standing Committee
The Standing Committee on Chemicals and Fertilizers is a crucial parliamentary body with a wide range of responsibilities, including:
- Budgetary Oversight: Scrutinizing the budget allocations for the Department of Pharmaceuticals, Department of Fertilizers, and Department of Chemicals and Petro Chemicals.
- Legislative Review: Examining bills related to the Ministry of Chemicals and Fertilizers.
- Performance Monitoring: Evaluating the annual performance of the Ministry and its departments.
- Policy Analysis: Analyzing national long-term policy documents related to the sector.
Impact of Past Committee Reports
Previous reports from the Standing Committee have had a significant influence on the pharmaceutical industry and drug regulatory landscape.
By delving into these critical areas, the Standing Committee seeks to contribute to a more affordable, accessible, and quality-assured pharmaceutical sector in India.
-
Why is the Standing Committee investigating drug price rise?
The Committee aims to identify the root causes of rising drug prices and recommend measures to control costs without compromising quality.
-
What are the key regulatory reforms being considered?
The Committee will explore potential reforms to strengthen drug approval processes, enhance post-market surveillance, and improve regulatory enforcement.
-
How can India achieve self-sufficiency in API production?
The Committee will assess the effectiveness of government initiatives like the PLI scheme and suggest additional strategies to boost domestic API manufacturing.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Digital Boost for Blood Centre Licensing in India
Maharashtra FDA gets a New Commissioner
Telangana DCA bust Pharmaceutical Company for illegal exports to Russia
Revised Schedule M to Take Effect from New Year: DCGI
Key Changes for Homoeopathic Medicines: GSR 669(E) dated 28-10-2024
Spurious Drug Racket Busted: Telangana DCA Seize Illegal Antibiotics
Navigating the Revised Schedule M: A Deep Dive into Vendor Validation and Audit
CDSCO approval granted for Anti Cancer Drug Olaparib
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
